U.S. awards contract to produce swabs for point-of-care test
The departments of Health and Human Services and Defense yesterday announced an $11.6 million contract to domestically produce more nasal swabs for the Cue Health molecular testing system, which detects the COVID-19 virus in about 20 minutes at the point of care.
The contract will allow Puritan Medical Products Company to expand domestic production capacity to 3 million per month by March 2021, the agencies said. HHS recently distributed 27,000 Cue Health test kits to Alaska, Florida, Louisiana, New Jersey and Texas for a pilot test. The Food and Drug Administration has authorized emergency use of the testing system in patient care settings operating under a CLIA certificate of waiver, compliance or accreditation.
Related News Articles
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…